SRS Overview
The Stereotactic Radiosurgery (SRS) Registry, launched in 2016, is an established multi-institutional registry focused on patients receiving stereotactic radiosurgery for primary cranial tumors, brain metastases and arteriovenous malformations (AVMs). This cross-cutting registry, assessing patient care in neurosurgery and radiation oncology, was developed in collaboration with the American Society for Radiation Oncology (ASTRO) and input from members of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Joint Section on Stereotactic and Functional Surgery and the Joint Section on Tumors. SRS operates on a web-based platform hosted by Brainlab (Quentry for SRS®).
Stereotactic Radiosurgery (SRS) has become an important part of the neurosurgical armamentarium. It is a minimally invasive approach using imaging guidance and stereotactic principles to deliver radiation to a target within or around the brain or spine. It is delivered in one to five sessions, in a high dose and with accuracy, precision and conformity that is in keeping with stereotactic neurosurgical principles. SRS is performed on a number of devices including Novalis (Brainlab), Gamma Knife (Elekta) and TruBeam (Varian), as well as others.
Goals of the SRS Registry
- Define national patterns of care in radiosurgery
- Provide benchmark data and quality improvement tools
- Yield information for clinicians and patients during the treatment process
- Improve health care outcomes and potentially lower the cost of care
- Facilitate the development of novel methods for effectiveness research
- Provide longitudinal data for outcome-related SRS studies
- Facilitate third parties’ access to robust data-driven insights
The SRS Registry is designed as a structured quality improvement project, a form of health effectiveness research that is focused on measuring and monitoring outcomes to secure positive change. The registry uses continuous data collection relating to clearly defined quality measures on patients undergoing SRS for the treatment of malignant and benign cranial tumors and AVMs. The registry generates relevant and useful treatment and outcomes data from real-world settings nationwide.